vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Opera Ltd (OPRA). Click either name above to swap in a different company.

Opera Ltd is the larger business by last-quarter revenue ($142.7M vs $75.1M, roughly 1.9× MEDIFAST INC).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Opera is a multinational technology corporation headquartered in Oslo, Norway, with additional offices in Europe, China, and Africa. Opera offers a range of products and services that include PC and mobile web browsers, GameMaker and gaming portals, the Opera News content recommendation products, the Opera Ads platform, and a number of Web3 and e-commerce products and services. The company's total user base is 296 million monthly active users.

MED vs OPRA — Head-to-Head

Bigger by revenue
OPRA
OPRA
1.9× larger
OPRA
$142.7M
$75.1M
MED

Income Statement — Q4 FY2025 vs Q1 FY2025

Metric
MED
MED
OPRA
OPRA
Revenue
$75.1M
$142.7M
Net Profit
$18.3M
Gross Margin
69.4%
Operating Margin
-10.4%
14.8%
Net Margin
12.8%
Revenue YoY
-36.9%
Net Profit YoY
EPS (diluted)
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
OPRA
OPRA
Q4 25
$75.1M
Q3 25
$89.4M
Q2 25
$105.6M
Q1 25
$115.7M
$142.7M
Q4 24
$119.0M
Q3 24
$140.2M
Q2 24
$168.6M
$211.6M
Q1 24
$174.7M
Net Profit
MED
MED
OPRA
OPRA
Q4 25
Q3 25
$-2.3M
Q2 25
$2.5M
Q1 25
$-772.0K
$18.3M
Q4 24
Q3 24
$1.1M
Q2 24
$-8.2M
$34.1M
Q1 24
$8.3M
Gross Margin
MED
MED
OPRA
OPRA
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
MED
MED
OPRA
OPRA
Q4 25
-10.4%
Q3 25
-4.6%
Q2 25
-1.0%
Q1 25
-1.1%
14.8%
Q4 24
0.6%
Q3 24
1.5%
Q2 24
-4.7%
19.6%
Q1 24
4.5%
Net Margin
MED
MED
OPRA
OPRA
Q4 25
Q3 25
-2.5%
Q2 25
2.3%
Q1 25
-0.7%
12.8%
Q4 24
Q3 24
0.8%
Q2 24
-4.8%
16.1%
Q1 24
4.8%
EPS (diluted)
MED
MED
OPRA
OPRA
Q4 25
$-1.64
Q3 25
$-0.21
Q2 25
$0.22
Q1 25
$-0.07
Q4 24
$0.08
Q3 24
$0.10
Q2 24
$-0.75
Q1 24
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
OPRA
OPRA
Cash + ST InvestmentsLiquidity on hand
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
Total Assets
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
OPRA
OPRA
Q4 25
$167.3M
Q3 25
$173.5M
Q2 25
$162.7M
Q1 25
$164.6M
Q4 24
$162.3M
Q3 24
$170.0M
Q2 24
$163.5M
Q1 24
$156.4M
Stockholders' Equity
MED
MED
OPRA
OPRA
Q4 25
$198.9M
Q3 25
$214.7M
Q2 25
$216.0M
Q1 25
$211.0M
Q4 24
$210.1M
Q3 24
$207.3M
Q2 24
$205.3M
Q1 24
$211.0M
Total Assets
MED
MED
OPRA
OPRA
Q4 25
$248.0M
Q3 25
$268.2M
Q2 25
$269.3M
Q1 25
$280.0M
Q4 24
$284.2M
Q3 24
$291.2M
Q2 24
$293.5M
Q1 24
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
OPRA
OPRA
Operating Cash FlowLast quarter
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
OPRA
OPRA
Q4 25
$-5.3M
Q3 25
$12.1M
Q2 25
$-3.4M
Q1 25
$3.4M
Q4 24
$-4.9M
Q3 24
$9.1M
Q2 24
$13.1M
Q1 24
$7.3M
Free Cash Flow
MED
MED
OPRA
OPRA
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
Q1 24
$5.4M
FCF Margin
MED
MED
OPRA
OPRA
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
Q1 24
3.1%
Capex Intensity
MED
MED
OPRA
OPRA
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
Q3 24
1.0%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
MED
MED
OPRA
OPRA
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons